Bayer initiates first-in-human trial for BAY2862789 in advanced solid tumors
Bayer has initiated a first-in-human clinical trial for BAY2862789, targeting advanced solid tumors, including non-small cell lung cancer (NSCLC).
Asset / Drug
Drug and asset intelligence for BAY2862789 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.